The Tyrosine Protein Phosphatase Non Receptor Type 1 pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Phosphatase Non Receptor Type 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tyrosine Protein Phosphatase Non Receptor Type 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Metabolic Disorders, Central Nervous System, and Genetic Disorders which include the indications Unspecified Cancer, Solid Tumor, Type 2 Diabetes, Obesity, Alzheimer’s Disease, Rett Syndrome, Duchenne Muscular Dystrophy, and Wilson Disease. It also reviews key players involved in Tyrosine Protein Phosphatase Non Receptor Type 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Tyrosine Protein Phosphatase Non Receptor Type 1 pipeline targets constitutes close to 21 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 4, 1, 3, and 4 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 5, and 4 molecule.
Tyrosine Protein Phosphatase Non Receptor Type 1 overview
Tyrosine-protein phosphatase non-receptor type 1 also known as protein-tyrosine phosphatase 1B (PTP1B) is an enzyme encoded by the PTPN1 gene. It acts as a regulator of endoplasmic reticulum unfolded protein response. It plays an important role in CKII- and p60c-src-induced signal transduction cascades. It regulates the EFNA5-EPHA3 signaling pathway which modulates cell reorganization and cell-cell repulsion. It mediates dephosphorylation of EIF2AK3/PERK, inactivating the protein kinase activity of EIF2AK3/PERK. It regulates the hepatocyte growth factor receptor signaling pathway through dephosphorylation of MET.
For a complete picture of Tyrosine Protein Phosphatase Non Receptor Type 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
